| |
Always Remission
|
Some Remission
|
No Remission
|
Significance
|
|---|
|
(n = 68)
|
(n = 376)
|
(n = 308)
| |
|---|
|
Females (%)
|
34 (50%)
|
299 (80%)
|
246 (80%)
|
P < 0.001*
|
|
Caucasian Ethnicity (%)
|
58 (85%)
|
287 (76%)
|
195 (63%)
|
P < 0.001*
|
|
Black African/Caribbean Ethnicity (%)
|
1 (2%)
|
37 (10%)
|
62 (20%)
|
P < 0.001*
|
|
Initial Mean Age In Years (SD)
|
54 (16)
|
55 (15)
|
56 (14)
|
NS**
|
|
Initial Disease Duration In Years (SD)
|
5 (5)
|
10 (9)
|
12 (11)
|
P = 0.003**
|
|
Initial Mean DAS28 (SD)
|
1.65 (0.65)
|
3.48 (1.32)
|
4.65 (1.19)
|
P < 0.001**
|
|
Overall Mean DAS28 (SD)
|
1.57 (0.45)
|
3.06 (0.71)
|
4.47 (0.82)
|
P < 0.001**
|
|
Any Flares (%)
|
27 (40%)
|
266 (71%)
|
194 (63%)
|
P < 0.001*
|
|
Overall Mean EQ5D-3 L (SD)
|
0.77 (0.17)
|
0.58 (0.24)
|
0.38 (0.28)
|
P < 0.001**
|
|
Initial Mean HAQ (SD)
|
0.31 (0.50)
|
1.06 (0.81)
|
1.58 (0.81)
|
P < 0.001**
|
|
Overall Mean HAQ (SD)
|
0.31 (0.45)
|
1.03 (0.70)
|
1.66 (0.67)
|
P < 0.001**
|
|
HAQ Below 0.50 On One Or More Occasion (%)
|
58 (85%)
|
180 (48%)
|
56 (18%)
|
P < 0.001*
|
- *Chi-Squared Testing **One Way Analysis Of Variance
